USA-based cancer specialist Epizyme today announced a collaboration with Chinese biotech Hutchmed to research, develop, manufacture and commercialize Tazverik (tazemetostat) in Greater China, including mainland China, Hong Kong, Macau and Taiwan (the Territory). 9 August 2021
BlueRock Therapeutics, a clinical stage biopharmaceutical company, a wholly-owned clinical-stage subsidiary of Germany’s Bayer, has revealed changes in its top executive team. 26 July 2021
GlaxoSmithKline has confirmed the current head of its consumer health joint venture (JV) will continue as chief executive once the unit is spun out into a standalone business. 23 July 2021
US oncology-focussed biotech Arcus Biosciences today announced that Dr Bill Grossman will transition out of his role as chief medical officer at Arcus and into a role at Gilead Sciences as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. 20 July 2021
Italian drugmaker Recordati’s board of directors has approved the appointment of Rob Koremans as chief executive effective December 1, 2021. 16 July 2021
Belgian cell therapy company Bone Therapeutics, which is addressing unmet medical needs in orthopedics and other diseases, has appointed Anne Leselbaum as chief medical officer (CMO), effective August 23, 2021. 12 July 2021
Boston, USA-based next-generation oncology company Scorpion Therapeutics says that Dr Axel Hoos will join the company as its new chief executive, effective August 2021. 8 July 2021
Dutch specialty pharma company Pharming Group said today it has appointed Anurag Relan as chief medical officer (CMO), effective immediately, and Robert Friesen as chief scientific officer, effective from August 1, 2021. 18 June 2021
Germany’s Merck KGaA is further pushing its science and technology based strategic growth trajectory with two appointments to key senior leadership positions on Group level. In both cases internal candidates will be promoted which underlines the high quality of Merck’s top talent pipeline. 1 June 2021
Specialty UK pharma company Shield Therapeutics, with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), today announced that Greg Madison has been appointed as chief executive, with effect from Tuesday, June 1, 2021. 28 May 2021
Capsida Biotherapeutics, a US biotech creating a new class of targeted gene therapies using its adeno-associated virus (AAV) engineering and cargo development platform, has named Swati Tole as the company’s first chief medical officer. 12 May 2021
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024